Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Oslo/Copenhagen, September 2nd, 2025 - SoftOx Solutions AS ("SoftOx" or "the Company" - TICKER: SOFTX) today announces a shift in its initial clinical focus towards chronic lung diseases in the upcoming proof-of-concept (POC) trial. It will evaluate the safety of SoftOx Inhalation Solution (SIS) across escalating doses and its effects on pulmonary bacterial load, thereby establishing a foundation for additional clinical advancements.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
